Donor organ’s blood type altered for the first time

The risk of rejection can be offset by carefully matching the molecular similarities between a donor and patient and making ...
Santé log

Eleva advances CPV-104 into Phase 1b clinical testing in patients with C3G, following the successful completion of single ascending dose evaluation in healthy volunteers

Preclinical studies have shown CPV-104 to be functionally equivalent to endogenous human Factor H, with the ability to normalize serum C3 levels and promote clearance of pathogenic complement deposits ...